Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Everolimus (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 13 Sep 2017 Status changed from active, no longer recruiting to completed.
- 11 Sep 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.
- 22 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 Feb 2018 as reported by ClinicalTrials.gov record.